| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
107,850,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Vaxcyte is a clinical-stage vaccine company. Co. is developing conjugate and protein vaccines to treat bacterial infectious diseases. Co.'s primary vaccine candidate, VAX-24, is a 24-valent investigational pneumococcal conjugate vaccine (PCV) for the treatment of invasive pneumococcal disease and pneumonia. Co.'s second PCV candidate, VAX-XP, is designed to expand the breadth of coverage to greater than 30 strains without compromising immunogenicity due to carrier suppression. In addition, Co.'s pipeline includes VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep and VAX-PG, a protein vaccine candidate targeting the keystone pathogen responsible for periodontitis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
124,527 |
289,711 |
366,947 |
559,547 |
| Total Sell Value |
$8,826,266 |
$19,152,247 |
$23,008,468 |
$28,095,276 |
| Total People Sold |
5 |
6 |
6 |
8 |
| Total Sell Transactions |
16 |
36 |
45 |
80 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Pickering Grant |
Chief Executive Officer |
• • – |
2021-05-27 |
4 |
OE |
$1.79 |
$21,920 |
D/D |
12,246 |
592,500 |
|
- |
|
| Fairman Jeff |
VP, Research |
• – – |
2021-04-22 |
4 |
OE |
$1.79 |
$4,999 |
D/D |
2,793 |
4,201 |
|
- |
|
| Sauer Paul |
SVP Process Dev, Manufacturing |
• – – |
2021-04-05 |
4 |
D |
$0.00 |
$0 |
D/D |
(38,308) |
39,591 |
|
- |
|
| Fairman Jeff |
VP, Research |
• – – |
2021-03-26 |
4 |
AS |
$23.64 |
$113,433 |
D/D |
(4,750) |
1,408 |
|
- |
|
| Fairman Jeff |
VP, Research |
• – – |
2021-03-26 |
4 |
OE |
$0.04 |
$190 |
D/D |
4,750 |
6,158 |
|
- |
|
| Pickering Grant |
President & CEO |
• • – |
2021-03-19 |
4 |
AS |
$25.77 |
$386,550 |
D/D |
(15,000) |
578,691 |
|
- |
|
| Pickering Grant |
President & CEO |
• • – |
2021-03-19 |
4 |
OE |
$1.79 |
$26,850 |
D/D |
15,000 |
593,691 |
|
- |
|
| Mitchell Jane Wright |
General Counsel |
• – – |
2021-03-15 |
4 |
AS |
$27.01 |
$68,239 |
D/D |
(2,500) |
1,562 |
|
- |
|
| Mitchell Jane Wright |
General Counsel |
• – – |
2021-03-15 |
4 |
OE |
$2.03 |
$5,075 |
D/D |
2,500 |
4,062 |
|
- |
|
| Sauer Paul |
SVP Process Dev, Manufacturing |
• – – |
2021-03-11 |
4 |
AS |
$25.00 |
$62,500 |
D/D |
(2,500) |
77,899 |
|
- |
|
| Sauer Paul |
SVP Process Dev, Manufacturing |
• – – |
2021-03-11 |
4 |
OE |
$1.79 |
$4,475 |
D/D |
2,500 |
80,399 |
|
- |
|
| Fairman Jeff |
VP, Research |
• – – |
2021-02-26 |
4 |
AS |
$23.73 |
$113,663 |
D/D |
(4,750) |
1,408 |
|
- |
|
| Fairman Jeff |
VP, Research |
• – – |
2021-02-26 |
4 |
OE |
$0.04 |
$190 |
D/D |
4,750 |
6,158 |
|
- |
|
| Wassil Jim |
Chief Operating Officer |
• – – |
2021-02-22 |
4 |
AS |
$26.43 |
$80,299 |
D/D |
(3,000) |
16,381 |
|
- |
|
| Wassil Jim |
Chief Operating Officer |
• – – |
2021-02-22 |
4 |
OE |
$2.42 |
$7,260 |
D/D |
3,000 |
19,381 |
|
- |
|
| Pickering Grant |
President & CEO |
• • – |
2021-02-22 |
4 |
AS |
$26.27 |
$397,036 |
D/D |
(15,000) |
578,691 |
|
- |
|
| Pickering Grant |
President & CEO |
• • – |
2021-02-22 |
4 |
OE |
$1.79 |
$26,850 |
D/D |
15,000 |
593,691 |
|
- |
|
| Mitchell Jane Wright |
General Counsel |
• – – |
2021-02-16 |
4 |
AS |
$26.95 |
$67,375 |
D/D |
(2,500) |
1,562 |
|
- |
|
| Mitchell Jane Wright |
General Counsel |
• – – |
2021-02-16 |
4 |
OE |
$2.03 |
$5,075 |
D/D |
2,500 |
4,062 |
|
- |
|
| Sauer Paul |
SVP Process Dev, Manufacturing |
• – – |
2021-02-11 |
4 |
AS |
$26.56 |
$66,624 |
D/D |
(2,500) |
77,899 |
|
- |
|
| Sauer Paul |
SVP Process Dev, Manufacturing |
• – – |
2021-02-11 |
4 |
OE |
$1.79 |
$4,475 |
D/D |
2,500 |
80,399 |
|
- |
|
| Hopfner Robert Lorne |
Director |
– • – |
2021-02-10 |
4 |
AS |
$25.75 |
$2,073,658 |
I/I |
(78,158) |
1,405,418 |
|
- |
|
| Hopfner Robert Lorne |
Director |
– • – |
2021-02-09 |
4 |
AS |
$27.12 |
$6,223,692 |
I/I |
(220,744) |
1,483,576 |
|
- |
|
| Hopfner Robert Lorne |
Director |
– • – |
2021-02-08 |
4 |
AS |
$25.64 |
$2,058,117 |
I/I |
(79,796) |
1,704,320 |
|
- |
|
| Hopfner Robert Lorne |
Director |
– • – |
2021-02-03 |
4 |
AS |
$25.06 |
$69,366 |
I/I |
(2,768) |
1,784,116 |
|
- |
|
355 Records found
|
|
Page 12 of 15 |
|
|
